In February 1994, the Pediatric AIDS Clinical Trial Group Protocol 076 demonstrated that zidovudine (ZDV) could reduce the risk of mother-to-child HIV transmission from 25% to 8% [1]. As a result, a United States Public Health Service (USPHS) task force issued recommendations in August 1994 for the use of ZDV to reduce perinatal HIV transmission. These guidelines were updated in July 2008 and include treatment options for HIV-infected pregnant women and for infants born to HIV-infected women.